Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial

Marisa Holubar, Aruna Subramanian, Natasha Purington, Haley Hedlin, Bryan Bunning, Katharine S. Walter, Hector Bonilla, Athanasia Boumis, Michael Chen, Kimberly Clinton, Liisa Dewhurst, Carol Epstein, Prasanna Jagannathan, Richard H. Kaszynski, Lori Panu, Julie Parsonnet, Elizabeth L. Ponder, Orlando Quintero, Elizabeth Sefton, Upinder Singh, Luke Soberanis, Henry Truong, Jason R. Andrews, Manisha Desai, Chaitan Khosla, Yvonne Maldonado
doi: https://doi.org/10.1101/2021.11.22.21266690
Marisa Holubar
1Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mholubar{at}stanford.edu
Aruna Subramanian
1Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: asubram2{at}stanford.edu
Natasha Purington
2Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Palo Alto, CA, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haley Hedlin
2Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Palo Alto, CA, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bryan Bunning
2Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Palo Alto, CA, USA
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katharine S. Walter
1Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hector Bonilla
1Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Athanasia Boumis
3Stanford Center for Clinical Research, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Chen
4Stanford Solutions, Stanford University School of Medicine, Stanford, CA 94305, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly Clinton
3Stanford Center for Clinical Research, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liisa Dewhurst
3Stanford Center for Clinical Research, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carol Epstein
5Carol L. Epstein MD Consulting LLC, Wellington, FL, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prasanna Jagannathan
1Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA
6Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard H. Kaszynski
4Stanford Solutions, Stanford University School of Medicine, Stanford, CA 94305, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lori Panu
3Stanford Center for Clinical Research, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Parsonnet
1Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA
7Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth L. Ponder
8Stanford ChEM-H, Stanford University, Stanford CA, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Orlando Quintero
1Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Sefton
8Stanford ChEM-H, Stanford University, Stanford CA, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Upinder Singh
1Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA
6Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luke Soberanis
3Stanford Center for Clinical Research, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry Truong
9Mariner Advanced Pharmacy Corp, San Mateo, California
PharmD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason R. Andrews
1Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manisha Desai
2Quantitative Sciences Unit, Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Palo Alto, CA, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chaitan Khosla
10Departments of Chemistry and Chemical Engineering, Stanford University, Stanford, CA, USA
8Stanford ChEM-H, Stanford University, Stanford CA, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yvonne Maldonado
11Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
7Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Favipiravir is an oral, RNA-dependent RNA polymerase inhibitor with in vitro activity against SARS-CoV2. Despite limited data, favipiravir is administered to patients with COVID-19 in several countries.

Methods We conducted a phase 2 double-blind randomized controlled outpatient trial of favipiravir in asymptomatic or mildly symptomatic adults with a positive SARS-CoV2 RT-PCR within 72 hours of enrollment. Participants were randomized 1:1 to receive placebo or favipiravir (1800 mg BID Day 1, 800mg BID Days 2-10). The primary outcome was SARS-CoV-2 shedding cessation in a modified intention-to-treat (mITT) cohort of participants with positive enrollment RT-PCRs. Using SARS-CoV-2 deep sequencing, we assessed favipiravir’s impact on mutagenesis.

Results From July 8, 2020 - March 23, 2021, we randomized 149 participants with 116 included in the mITT cohort. The participants’ mean age was 43 years (SD 12.5) and 57 (49%) were women. We found no difference in time to shedding cessation by treatment arm overall (HR 0.76 favoring placebo, 95% confidence interval [CI] 0.48 – 1.20) or in sub-group analyses (age, sex, high-risk comorbidities, seropositivity or symptom duration at enrollment). We observed no difference in time to symptom resolution (initial: HR 0.84, 95% CI 0.54 – 1.29; sustained: HR 0.87, 95% CI 0.52 – 1.45). We detected no difference in accumulation of transition mutations in the viral genome during treatment.

Conclusions Our data do not support favipiravir use at commonly used doses in outpatients with uncomplicated COVID-19. Further research is needed to ascertain if higher doses of favipiravir are effective and safe for patients with COVID-19.

Trial registration number NCT04346628

Summary In this phase 2 double-blind randomized controlled outpatient trial of favipiravir in asymptomatic or uncomplicated patients with COVID-19, we found no difference in time to shedding cessation or time to symptom resolution by treatment arm.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04346628

Funding Statement

This study was funded by anonymous donors to Stanford University. The funders had no role in data collection, analysis, or the decision to publish.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB of Stanford University School of Medicine gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 24, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial
Marisa Holubar, Aruna Subramanian, Natasha Purington, Haley Hedlin, Bryan Bunning, Katharine S. Walter, Hector Bonilla, Athanasia Boumis, Michael Chen, Kimberly Clinton, Liisa Dewhurst, Carol Epstein, Prasanna Jagannathan, Richard H. Kaszynski, Lori Panu, Julie Parsonnet, Elizabeth L. Ponder, Orlando Quintero, Elizabeth Sefton, Upinder Singh, Luke Soberanis, Henry Truong, Jason R. Andrews, Manisha Desai, Chaitan Khosla, Yvonne Maldonado
medRxiv 2021.11.22.21266690; doi: https://doi.org/10.1101/2021.11.22.21266690
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial
Marisa Holubar, Aruna Subramanian, Natasha Purington, Haley Hedlin, Bryan Bunning, Katharine S. Walter, Hector Bonilla, Athanasia Boumis, Michael Chen, Kimberly Clinton, Liisa Dewhurst, Carol Epstein, Prasanna Jagannathan, Richard H. Kaszynski, Lori Panu, Julie Parsonnet, Elizabeth L. Ponder, Orlando Quintero, Elizabeth Sefton, Upinder Singh, Luke Soberanis, Henry Truong, Jason R. Andrews, Manisha Desai, Chaitan Khosla, Yvonne Maldonado
medRxiv 2021.11.22.21266690; doi: https://doi.org/10.1101/2021.11.22.21266690

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3294)
  • Dentistry and Oral Medicine (364)
  • Dermatology (280)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13378)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5155)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3271)
  • Health Policy (1141)
  • Health Systems and Quality Improvement (1191)
  • Hematology (431)
  • HIV/AIDS (1018)
  • Infectious Diseases (except HIV/AIDS) (14632)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4927)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (725)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4214)
  • Public and Global Health (7506)
  • Radiology and Imaging (1706)
  • Rehabilitation Medicine and Physical Therapy (1014)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (498)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)